Remission of infantile generalized myofibromatosis after interferon alpha therapy

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 2, 2008, Pages 179-181

  Auriti, Cinzia ^a   Kieran, Mark W ^b   Deb, Giovanni ^c   Devito, Rita ^a   Pasquini, Luciano ^c   Danhaive, Olivier ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Department of Oncology ^*  (Italy)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Interferon alpha 2b; Vascular endothelial growth factor; Visceral myofibroma

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; RECOMBINANT ALPHA2B INTERFERON; SMOOTH MUSCLE ACTIN; VASCULOTROPIN; ALPHA2B INTERFERON; VASCULOTROPIN A;

ARTICLE; CANCER REGRESSION; CASE REPORT; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FEVER; HEART TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LEIOMYOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR BIOPSY; BLOOD; URINE;

FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFANT; INTERFERON ALFA-2B; MYOFIBROMATOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41949101467     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31815e62bb     Document Type: Article

References (25)

1. Wiswell TE, Davis J, Cunningham BE, et al. Infantile myofibromatosis: the most common fibrous tumor of infancy. J Pediatr Surg. 1988;23:315-318.
2. Hatzidaki E, Korakaki E, Voloudaki A, et al. Infantile myofibromatosis with visceral involvement and complete spontaneous regression. J Dermatol. 2001;28:379-382.
3. Folkman J. What is the evidence that tumors are angiogenesisdependant? J Natl Cancer Institute. 1990;82:4-6.
4. Poon RTP, Fant ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19: 1207-1225.
5. Giavazzi R, Sennino B, Coltrini D, et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumour growth and angiogenesis. Am J Pathol. 2003;162:1913-1925.
6. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-742.
7. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27:573-581.
8. Tabone MD, Landman-Parker J, Arcil B, et al. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res. 2001;7:538-543.
9. Choi SH, Park EY, Jung HL, et al. Vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion. J Korean Med Sci. 2006;21:608-613.
10. de Montpreville VT, Zemoura L, Vaksmann G, et al. Endocardial location of familial myofibromatosis revealed by cerebral embolization: cardiac counterpart of the frequent intravascular growth of the disease? Virchows Arch. 2004;444:300-303.
11. Day M, Edwards AO, Weinberg A, et al. Successful therapy of a patient with infantile generalized myofibromatosis. Med Pediatr Oncol. 2002;38:371-373.
12. Savasan S, Fulgenzi LA, Rabah R, et al. Generalized infantile myofibromatosis in a patient with Turner's syndrome: a trial of interferon alpha. J Pediatr. 1998;133:694-696.
13. Singh RK, Gutman M, Bucana CD, et al. Interferons a and b downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci. 1995;92:4562-4566.
14. Marler JJ, Rubin JB, Trede NS, et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alpha 2b: report of two cases. Pediatrics. 2002;109:e37.
15. Kaban LB, Mulliken JB, Ezekowitz RA, et al. Antiangiogenic therapy of a recurrent giant cell tumour of the mandible with interferon alfa-2a. Pediatrics. 1999;103:1145-1149.
16. Deb G, Jenkner A, De Sio L, et al. Spindle cell (kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with a-2a Interferon. Med Pediatr Oncol. 1997;28:358-361.
17. Leithner A, Schnack B, Katterschakfa T, et al.Treatment of extraabdominal desmoid tumours with interferon-alfa with or without tretinoin. J Surg Oncol. 2000;73:21-25.
18. Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr. 1999;135: 782-785.
19. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1995; 333:556-596.
20. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangioma of infancy. J Pediatr. 1998;132:527-530.
21. Deb G, Jenkner A, Donfrancesco A. Spastic diplegia and interferon. J Pediatr. 1999;134:382-385.
22. Stenman G, Nadal N, Persson S, et al. Del(6)(q12q15) as the sole cytogenetic anomaly in a case of solitary infantile myofibromatosis. Oncol Rep. 1999;6:1101-1104.
23. Coffin CM, Neilson KA, Ingels S, et al. Congenital generalized myofibromatosis: a disseminated angiocentric myofibromatosis. Pediatr Pathol Lab Med. 1995;15:571-587.
24. Lèautè -Labrè ze C, Labarthe MP, Blanc JF, et al. Self-healing generalized infantile myofibromatosis with elevated urinary bFGF. Pediatr Derm. 2001;18:305-307.
25. Presta M, Dell'Era P, Mitola P, et al. Fibroblast growth factor/ fibroblast growth factor receptor system in angiogenesis. Cytok Growth Fact Rev. 2005;16:159-178.